Fulcrum Therapeutics (NASDAQ:FULC) Coverage Initiated by Analysts at JPMorgan Chase & Co.

Research analysts at JPMorgan Chase & Co. initiated coverage on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a research note issued on Monday,Benzinga reports. The firm set an “overweight” rating and a $20.00 price target on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 103.05% from the stock’s current price.

Several other analysts also recently weighed in on the company. HC Wainwright boosted their target price on Fulcrum Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Monday, December 8th. Citigroup reiterated an “underperform” rating on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. The Goldman Sachs Group reissued a “positive” rating on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada increased their price target on shares of Fulcrum Therapeutics from $7.00 to $10.00 and gave the stock a “sector perform” rating in a research note on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.11.

Fulcrum Therapeutics Trading Down 2.6%

Fulcrum Therapeutics stock opened at $9.85 on Monday. The company has a fifty day simple moving average of $10.69 and a 200-day simple moving average of $8.77. The stock has a market cap of $533.06 million, a P/E ratio of -8.35 and a beta of 3.20. Fulcrum Therapeutics has a 12-month low of $2.32 and a 12-month high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). As a group, sell-side analysts forecast that Fulcrum Therapeutics will post -0.16 earnings per share for the current fiscal year.

Insider Activity at Fulcrum Therapeutics

In other Fulcrum Therapeutics news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the transaction, the insider owned 6,053,960 shares of the company’s stock, valued at $84,634,360.80. This trade represents a 40.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total transaction of $178,050.00. Following the sale, the director directly owned 469,864 shares of the company’s stock, valued at $5,577,285.68. This represents a 3.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 4,205,139 shares of company stock worth $58,711,943 over the last three months. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of Fulcrum Therapeutics

Institutional investors have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. increased its position in Fulcrum Therapeutics by 53.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock worth $31,572,000 after purchasing an additional 1,589,000 shares in the last quarter. Balyasny Asset Management L.P. purchased a new stake in Fulcrum Therapeutics during the 2nd quarter worth $9,207,000. Invesco Ltd. increased its holdings in Fulcrum Therapeutics by 448.4% in the 2nd quarter. Invesco Ltd. now owns 470,333 shares of the company’s stock valued at $3,236,000 after purchasing an additional 384,566 shares in the last quarter. Nantahala Capital Management LLC raised its position in Fulcrum Therapeutics by 8.9% in the third quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock valued at $42,971,000 after purchasing an additional 382,485 shares during the period. Finally, Boothbay Fund Management LLC lifted its stake in shares of Fulcrum Therapeutics by 104.2% during the third quarter. Boothbay Fund Management LLC now owns 678,414 shares of the company’s stock worth $6,241,000 after purchasing an additional 346,136 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.